Corebridge Financial Inc. Decreases Holdings in Medpace Holdings, Inc. (NASDAQ:MEDP)

Corebridge Financial Inc. reduced its position in Medpace Holdings, Inc. (NASDAQ:MEDP) by 4.1% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 29,131 shares of the company’s stock after selling 1,230 shares during the quarter. Corebridge Financial Inc.’s holdings in Medpace were worth $9,678,000 at the end of the most recent reporting period.

A number of other large investors have also made changes to their positions in MEDP. Centaurus Financial Inc. grew its stake in Medpace by 2.0% during the 3rd quarter. Centaurus Financial Inc. now owns 1,513 shares of the company’s stock worth $505,000 after buying an additional 29 shares during the last quarter. Lindbrook Capital LLC grew its stake in shares of Medpace by 27.6% during the fourth quarter. Lindbrook Capital LLC now owns 134 shares of the company’s stock worth $45,000 after acquiring an additional 29 shares during the last quarter. HBK Sorce Advisory LLC increased its holdings in shares of Medpace by 0.5% during the fourth quarter. HBK Sorce Advisory LLC now owns 5,384 shares of the company’s stock valued at $1,789,000 after acquiring an additional 29 shares in the last quarter. Assetmark Inc. raised its position in shares of Medpace by 20.1% in the 4th quarter. Assetmark Inc. now owns 173 shares of the company’s stock valued at $57,000 after purchasing an additional 29 shares during the last quarter. Finally, Proficio Capital Partners LLC boosted its stake in Medpace by 4.1% in the 4th quarter. Proficio Capital Partners LLC now owns 730 shares of the company’s stock worth $243,000 after purchasing an additional 29 shares in the last quarter. 77.98% of the stock is owned by institutional investors and hedge funds.

Medpace Stock Down 2.1 %

Medpace stock opened at $317.65 on Thursday. The business’s 50-day moving average price is $336.81 and its 200 day moving average price is $339.41. The firm has a market cap of $9.68 billion, a price-to-earnings ratio of 25.15, a price-to-earnings-growth ratio of 3.81 and a beta of 1.47. Medpace Holdings, Inc. has a 52 week low of $302.01 and a 52 week high of $459.77.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings data on Monday, February 10th. The company reported $3.67 EPS for the quarter, topping analysts’ consensus estimates of $2.96 by $0.71. Medpace had a net margin of 19.17% and a return on equity of 51.48%. Equities analysts expect that Medpace Holdings, Inc. will post 12.29 EPS for the current year.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on MEDP shares. Leerink Partnrs raised shares of Medpace to a “hold” rating in a report on Monday. Leerink Partners initiated coverage on Medpace in a research report on Monday. They set a “market perform” rating and a $330.00 price target for the company. Finally, Robert W. Baird increased their price objective on Medpace from $354.00 to $362.00 and gave the company a “neutral” rating in a report on Monday, January 27th. Nine analysts have rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat.com, Medpace presently has an average rating of “Hold” and a consensus target price of $376.30.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.